PD1抑制剂治疗患者单核细胞IL10表达降低预示严重免疫相关不良事件
研究对43例接受PD1阻断治疗的癌症患者进行纵向流式细胞术免疫监测,于治疗前及第2/4/6周期前采血。结果显示,严重免疫相关不良事件(s-irAE)患者单核细胞受刺激后IL10产生减少,体外可解除对T细胞增殖的抑制,可能解释其活化T细胞扩增。
要点
- PD1阻断治疗前未见与临床结局相关的固有免疫模式,治疗中才出现队列特异性免疫改变。
- s-irAE患者单核细胞受刺激后IL10产生减少,体外对T细胞增殖的抑制被削弱。
- 应答者活化T和NK细胞亚群增加,ex vivo刺激后高表达IFNγ和TNFα。
核心结论
- 治疗触发的免疫变化可区分临床相关队列,可能有助于更好的患者分层,并为s-irAE发病机制提供新见解。
研究设计与样本
- 纵向评估PD1阻断对新鲜全血免疫系统的影响,采用流式细胞术细胞定量并分析各主要免疫群体经细胞类型特异性刺激后的效应特性。
- 招募43例接受PD1阻断的癌症患者,于治疗前及第2/4/6周期前评估,收集超过30,000个流式细胞术数据值。
主要发现
- PD1阻断开始前未观察到与临床结局相关的固有免疫模式,治疗期间出现队列特异性免疫改变。
- 应答者最突出的变化是活化T和NK细胞亚群增加,ex vivo刺激后高表达IFNγ和TNFα。
- s-irAE患者活化CD4+和CD8+ T细胞数量与无/轻度irAE患者类似增加,但缺乏应答者与非应答者之间的功能差异。
- s-irAE患者单核细胞受刺激后IL10产生减少,体外对T细胞增殖的抑制被削弱,可能解释其T细胞扩增。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite remarkable clinical efficacy, little is known about the system-wide immunological alterations provoked by PD1 blockade. Dynamics of quantitative immune composition and functional repertoire during PD1 blockade could delineate cohort-specific patterns of treatment response and therapy-induced toxicity. METHODS: We longitudinally assessed therapy-induced effects on the immune system in fresh whole blood using flow cytometry-based cell quantifications, accompanied by analyses of effector properties of all major immune populations upon cell-type specific stimulations. 43 cancer patients undergoing PD1 blockade were recruited with assessments performed pre-treatment and before cycles 2/4/6, which resulted in the collection of more than 30,000 cytometric data values. RESULTS: We observed no intrinsic immune pattern correlating with clinical outcome before PD1 blockade initiation, but cohort-specific immune alterations emerged during therapy. The most striking evolving changes in therapy responders were an increase in activated T and NK cell subsets, which showed high IFNγ and TNFα expression upon ex vivo stimulation. Patients affected by severe immune-related adverse events (s-irAE) presented with an analogously increased number of activated CD4 + and CD8 + T cells compared to patients with no/mild irAE, but lacked the functional divergences observed between responders versus non-responders. Instead, their monocytes showed discriminatory functional deficits with less IL10 production upon stimulation, which led to an abrogated inhibition of T cell proliferation in vitro and thus may account for the observed T cell expansion in patients with s-irAE. CONCLUSION: Our holistic explorative approach allowed the delineation of clinically relevant cohorts by treatment-triggered immune changes, potentially enabling better patient stratification and further revealed new mechanistic insights into the pathogenesis of s-irAE.
引用
- Rosnev S, Sterner B, Schiele P, et al. Reduced monocytic IL10 expression in PD1 inhibitor-treated patients is a harbinger of severe immune-related adverse events. Eur J Cancer. 2025. PMID: 39848112. doi:10.1016/j.ejca.2025.115252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。